Sutent Gets Regular FDA Approval for RCC

Article

FDA officials have granted regular approval to Sutent (sunitinib malate, Pfizer) for the treatment of advanced renal cell carcinoma (RCC) patients who failed prior cytokine-based therapy, upgrading it from the accelerated approval granted in January 2006.

ROCKVILLE, Maryland—FDA officials have granted regular approval to Sutent (sunitinib malate, Pfizer) for the treatment of advanced renal cell carcinoma (RCC) patients who failed prior cytokine-based therapy, upgrading it from the accelerated approval granted in January 2006. The new labeling also includes the first-line use of Sutent for treating advanced RCC.

The agency gave the drug, an oral multikinase inhibitor, initial marketing approval for two indications simultaneously last year—advanced RCC and gastrointestinal stromal tumors. Sutent received its RCC approval on the basis of partial-response and response-duration rates obtained in two single-arm, multicenter clinical studies. FDA based its decision to upgrade Sutent's approval status on an interim analysis of a large phase III trial showing clinical benefit in patients treated with the drug (N Engl J Med 356:115-124, 2007).

The trial randomized 750 treatment-naive metastatic RCC patients to Sutent or interferon-alfa. Sutent-treated patients had significantly longer median progression-free survival: 11 months vs 5 months for interferon (HR 0.42). The Sutent group had a 27.5% response rate vs 5.3% for IFN. Overall survival data have not reached maturity.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.